Gender and disease features in Moroccan patients with ankylosing spondylitis.
ABSTRACT This study was conducted to determine differences in ankylosing spondylitis (AS) between men and women in terms of clinical characteristics, biological features, structural severity and quality of life (QoL). A total of 130 consecutive AS patients fulfilling the modified New York criteria were included. Sociodemographic data were collected. The activity of disease was assessed by the Bath ankylosing spondylitis disease activity index (BASDAI) and the functional disability by the Bath Ankylosing spondylitis functional index (BASFI). Spinal mobility was measured using the occiput-to-wall distance, chest expansion, Schober index and the Bath Ankylosing Spondylitis Metrology Index (BASMI). The Bath Ankylosing Spondylitis Radiologic Index (BASRI) was used to evaluate structural damage. Fatigue was evaluated using a visual analogue scale and the QoL was measured by using the generic instrument SF-36. Laboratory tests included the erythrocyte sedimentation rate (ESR) and the C-reactive protein (CRP). In our sample, there were 87 (66.9%) men and 43 (33.1%) women. Women had significantly lower educational levels but there were no differences in socioeconomic status, age at onset, diagnosis delay, disease duration or treatments. Also, women had higher clinical disease activity (morning stiffness and BASDAI score), higher number of tender joints, more severe enthesitis and higher scores of fatigue (for all p ≤ 0.05). Moreover, hip involvement was more prevalent in men and the impairment of spinal mobility was significantly worse compared to women (for all p ≤ 0.001). Men had worse radiographic damage and lower scores in physical and social domains of QoL, but there were no differences in functional impairment scores. In this study, we noticed that AS presents differently according to gender in our patients. More longitudinal studies seem to be necessary to identify gender-related parameters of disease, thing that may help in diagnosis and therapeutic management of our AS patients.
- [Show abstract] [Hide abstract]
ABSTRACT: Hintergrund Beim Morbus Bechterew (ankylosierende Spondylitis, AS) sind laut neuerer Literatur einige geschlechtsspezifische Besonderheiten aufgefallen. Material und Methode Ziel der Arbeit war es, basierend auf einer Literaturrecherche einen Überblick zu diesem Thema zu geben. Ergebnisse Männer sind etwa doppelt so häufig von M. Bechterew betroffen als Frauen. Bei Frauen ist der entzündliche Charakter der Erkrankung in Achse und Peripherie oft stärker, radiologische Zeichen und AS-typische Einsteifung der Wirbelsäule sind später und seltener, hypermobile/instabile Segmente können bleiben. Die Schmerzen sind mindestens gleich stark, Funktionseinschränkung und Erschöpfung bei Frauen stärker als bei Männern ausgeprägt. Schlussfolgerung Die AS verläuft bei Frauen nicht milder, aber oft anders als bei Männern.Manuelle Medizin 03/2013; 51(1). DOI:10.1007/s00337-012-0995-3
- Turkish journal of rheumatology 01/2013; 28(2):117-122. · 0.23 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Ankylosing spondylitis (AS) is an inflammatory rheumatologic disease characterized by inflammation and progressive structural damage of the affected joints. Hip involvement often results in severe deformities and significant impairment on function. Although, tremendous progress has been made in conservative management for AS, effective prevention strategies for hip involvement and long-term need for total hip arthroplasty (THA) remain indefinite. When hip involvement has progressed to intractable pain and disability, THA is still the most effective treatment strategy to relieve pain and restore function. However, certain AS-specific problems regarding "preoperative preparation," "intraoperative difficulties," "perioperative pharmacological management," "postoperative physiotherapy," "operation benefits," and "operation complications" need more concern and further discussion.Clinical Rheumatology 04/2013; 32(8). DOI:10.1007/s10067-013-2278-3 · 1.77 Impact Factor